Sector
PharmaceuticalsOpen
₹188.5Prev. Close
₹188.08Turnover(Lac.)
₹1,579.99Day's High
₹192.06Day's Low
₹184.0452 Week's High
₹240.752 Week's Low
₹116.4Book Value
₹44.07Face Value
₹2Mkt Cap (₹ Cr.)
4,682.9P/E
242.92EPS
0.77Divi. Yield
0Viyash manufactures active pharmaceutical ingredients (APIs) and drug formulations for the human health segment.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 49.89 | 49.89 | 58.81 | 49.67 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,037.34 | 1,008.48 | 982.28 | 979.84 |
Net Worth | 1,087.23 | 1,058.37 | 1,041.09 | 1,029.51 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 265.45 | 227.33 | 106 | 90.71 |
yoy growth (%) | 16.77 | 114.45 | 16.85 | -77.01 |
Raw materials | -108.86 | -113.04 | -79.37 | -72.52 |
As % of sales | 41.01 | 49.72 | 74.87 | 79.94 |
Employee costs | -22.41 | -17.09 | -11.85 | -17.9 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 43.44 | 22.81 | 1.82 | -15.16 |
Depreciation | -9.12 | -8.95 | -3.66 | -3.25 |
Tax paid | -8.77 | -1.47 | -2.86 | 0 |
Working capital | 33.97 | -80.01 | -110.8 | 56.46 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 16.77 | 114.45 | 16.85 | -77.01 |
Op profit growth | 58.69 | -220.94 | -39.83 | -186.01 |
EBIT growth | 65.64 | 1,156.67 | -115.03 | -154.81 |
Net profit growth | 50.47 | -94.74 | -33,86,825 | -100.11 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 1,551.37 | 1,369.73 | 1,420.91 | 1,412.82 | 1,361.62 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,551.37 | 1,369.73 | 1,420.91 | 1,412.82 | 1,361.62 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 14.69 | 10.96 | 6.39 | 10.85 | 8.36 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.6 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,484 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.1 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,164 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non-Exec. & Independent Dir.
Kausalya Santhanam
Joint Managing Director
Sharat Narasapur
Non-Exec & Non-Independent Dir
Neeraj Bharadwaj
Non-Exec & Non-Independent Dir
Gregory John Andrews
Non-Exec & Non-Independent Dir
Fabian Kausche
Chairman & Independent Directo
Kamal K Sharma
Non-Exec. & Independent Dir.
Milind Sarwate
Managing Director & CEO
N Rajaram
Non Executive Director
Hari Babu Bodepudi
Company Sec. & Compli. Officer
PHILLIP TROTT
301 Dosti Pinnacle 3rd Floor,
Plot E7 Road No 22 Wagle Indl,
Maharashtra - 400604
Tel: 91-022-41114777
Website: http://www.sequent.in
Email: investors@sequent.in
19/20 Jaferbhoy Ind,
1st Floor Makwana Rd, Marol Naka,
Mumbai - 400 059
Tel: 91-022-28594060
Website: www.adriotcorporate.com
Email: info@adroitcorporate.com
Summary
Visistha Traders & Finance Ltd, has amalgamated PI Drugs & Pharmaceuticals Ltd with itself. The High court has sanctioned the Scheme of Amalgamation and the same was filed with ROC by the company on N...
Read More
Reports by Sequent Scientific Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.